About
Travere Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Today
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
May 5 2026
Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Apr 27 2026
Travere Therapeutics to Report First Quarter 2026 Financial Results
Apr 14 2026
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS
Apr 13 2026
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
Translate